Iterum Therapeutics PLC (NAS:ITRM)
$ 2.24 -0.15 (-6.28%) Market Cap: 61.63 Mil Enterprise Value: 73.70 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 35/100

Q1 2021 Iterum Therapeutics PLC Earnings Call Transcript

May 14, 2021 / 12:30PM GMT
Release Date Price: $14.52 (+8.25%)
Louise Barrett
Iterum Therapeutics plc - SVP of Legal Affairs & Secretary

Good morning, and welcome to Iterum Therapeutics' First Quarter 2021 Financial Results Conference Call. A press release with the company's first quarter results was issued earlier this morning and can be found on our website. We are joined this morning by Corey Fishman, CEO; and Judy Matthews, CFO. Corey will provide some opening remarks. Judy will provide details on our financial results, and then we'll open the lines for Q&A.

Before we begin, I would just like to remind you that this call will contain forward-looking statements concerning our plans, strategies and prospects for our business, including with respect to the timing of review for the FDA of our NDA for oral sulopenem and related PDUFA date; the holding of an FDA Advisory Committee meeting to discuss the NDA; our expectations for potential approval on the PDUFA date; the market potential for sulopenem; commercialization activities, including the ability to enter into a definitive agreement with respect to commercialization services and to successfully

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot